Large porous particles for respiratory drug delivery. Glycine-based formulations

Ogienko, A. G.; Bogdanova, Ekaterina; Trofimov, N.A.; Myz, S. A.; Kolesov, B. A.; Yunoshev, A. S.; Zubikov, N.V.; Manakov, A. Yu.; Болдырев, В. В.; Boldyreva, Elena V.

doi:10.1016/j.ejps.2017.05.007

Cited by 31 publications

(28 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Either particles are made with standard density with geometric diameters between 0.5 and 5 µm, or they are created with a non-standard density with aerodynamic diameters between 0.5 and 5 µm in contrast to geometric diameters outside the standard range. Conventional DPIs use the first strategy, whereas large porous particles provide an example of the second strategy [ 6 , 7 ]. Large porous particles are recently becoming popular as the technique for both local and systemic applications by the pulmonary route to the lungs [ 8 , 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation

et al. 2020

View full text Add to dashboard Cite

Recently, statistical techniques such as design of experiments are being applied for efficient optimization of oral formulations. To use these statistical techniques for inhalation formulations, efficient methods for rapid determination of the aerodynamic particle size distribution of many samples are needed. Therefore, we aimed to develop a simple method to measure aerodynamic particle size distribution that closely agrees with the results of inhalation characteristic tests. We added attachments for dispersion to the aerodynamic particle sizer (APS) so that formulations could be dispersed under the same condition as for multi-stage liquid impinger (MSLI) measurement. Then, we examined the correlation between MSLI and APS using lyophilizate for dry powder inhalation formulations that generate porous particles just on inhalation. It is difficult to obtain the accurate aerodynamic particle size distribution of porous particles by APS because the particle density is difficult to estimate accurately. However, there was a significant correlation between MSLI and APS when the particle density settings for APS measurement was calculated by a conversion factor based on the result of MSLI. The APS with dispersion attachments and this conversion factor can measure a number of samples in a short time, thereby enabling more efficient optimization of dry powder inhalers.

show abstract

Section: Introductionmentioning

confidence: 99%

Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Particles with low density have better flowability and can be delivered to the lung easier with higher deposition (Bosquillon et al, 2001). An exact density value is not clearly established, but most of the studies consider the DPI "low density" from a tap density around 0.4-0.1 g/cm 3 or lower (Ogienko et al, 2017;Ógáin et al, 2011;Watts et al, 2013). Large porous particles (LPPs) can be obtained using porogen agents (e.g.…”

Section: Introductionmentioning

confidence: 99%

Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery

Chvatal

Ambrus

Party

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large size (>5 µm) and low density (<0.2 mg/cm 3) formulations. With the appropriate amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8%, while the emitted fraction (EF) reached 85.4%, both higher than for the non-porous particles. Stability tests demonstrated that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the first time large porous particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are reported.

show abstract

“…Large porous particle (LPP) technology was first described more than 20 years ago, but has recently gained in popularity [43, 44]. LPPs are characterised by particles of low mass density (<0.1 g·cm −3 ) but large physical size (5–30 µm) and are useful for both local and systemic applications.…”

Section: What Are the Current Incentives Driving Inhaler Development mentioning

confidence: 99%

“…LPPs are especially attractive for systemic inhalation therapies, as their high delivery efficiency and sustained drug release properties allow increased systemic bioavailability. LPPs are commonly produced by spray drying or spray freeze-drying technology [44] and the rapid expansion of supercritical fluids [45]. …”

Section: What Are the Current Incentives Driving Inhaler Development mentioning

confidence: 99%

Is there room for further innovation in inhaled therapy for airways disease?

Biddiscombe

Usmani

2018

Breathe

View full text Add to dashboard Cite

Inhaled medication is the cornerstone in the treatment of patients across a spectrum of respiratory diseases including asthma and chronic obstructive pulmonary disease. The benefits of inhaled therapy have long been recognised but the most important innovations have occurred over the past 60 years, beginning with the invention of the pressurised metered dose inhaler. However, despite over 230 different device and drug combinations currently being available, disease control is far from perfect.Here we look at how innovation in inhaler design may improve treatments for respiratory diseases and how new formulations may lead to treatments for diseases beyond the lungs. We look at the three main areas where innovation in inhaled therapy is most likely to occur: 1) device engineering and design; 2) chemistry and formulations; and 3) digital technology associated with inhalers. Inhaler design has improved significantly but considerable challenges still remain in order to continually innovate and improve targeted drug delivery to the lungs. Healthcare professionals want see innovations that motivate their patients to achieve their goal of improving their health, through better adherence to treatment. Patients want devices that are easy to use and to see that their efforts are rewarded by improvements in their condition.Key pointsThe dictionary definition of innovation is the introduction of new things, ideas or ways of doing something. We show how this definition can be applied to inhaled therapy.We take a look at the past to see what drove innovation in inhaler design and how this has led to the current devices.We look at the current drivers of innovation in engineering, chemistry and digital technology and predict how this may translate to new devices.Can innovation help the healthcare professional manage their patients better?What does the patient expect from innovation in their device?Educational aimsTo understand the importance of inhaled medication in the treatment of lung diseases.To understand how innovation has helped advance some of the devices patients use today from basic and inefficient designs.To understand the obstacles that prevent patients from receiving optimal treatment from their inhalers.To understand how innovation in inhaler design can lead to improved treatment for patients and widen the range of diseases that can be treated via the inhaled route.

show abstract

Large porous particles for respiratory drug delivery. Glycine-based formulations

Cited by 31 publications

References 58 publications

Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation

Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation

Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery

Is there room for further innovation in inhaled therapy for airways disease?

Contact Info

Product

Resources

About